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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the analgesic efficacy, and adverse events, of pharmacological interventions used to treat acute painful sickle cell vaso-occlusive
crises in adults, aged 18 and over, in any setting.
B A C K G R O U N D
A previous review, titled ’Pain management for sickle cell disease
in children and adults’ was withdrawn as it was out of date (
Dunlop 2014). This is a completely new review focusing only on
the painful vaso-occlusive crises (or episodes) of sickle cell disease
and it excludes the paediatric population.
Description of the condition
Sickle cell disease is a generic term for a group of inherited disor-
ders of haemoglobin (Hb) structure in which the affected person
inherits two mutant globin genes (one from each parent), at least
one of which is always the sickle mutation (WHO 2010). The
latter results from a single nucleotide change (GAT→GTT) in
the sixth codon of exon 1 of the β-globin gene responsible for the
synthesis of the β-globin chain. The resulting replacement of the
normal glutamic acid by valine at position 6 in the β chain leads
to the formation of sickle Hb (Hb S). Sickle cell anaemia is the
homozygous state, in which the sickle gene is inherited from both
parents. Other sickle cell syndromes result from the co-inheritance
of the sickle gene and a non-sickle gene, such as in Hb C, Hb
OArab, Hb D, β+-thalassaemia, or β0-thalassemia (NIH 2014).
The abnormally shaped red blood cell was first described by JB
Herrick in 1910 (Herrick 1910). Sickle cell originated in Sub-Sa-
haranAfrica and the Indian subcontinent (Stuart 2004;Weatherall
2006; Martí-Carvajal 2009), but has persisted as a recessive trait
due to the survival advantage against malaria enjoyed by people
with the heterozygote form (Weatherall 2001). If location were
the key determinant, people of African, Mediterranean, Middle
Eastern, Indian and Latin-American descent would be perceived
at highest risk (Sasongko 2013). However, in recent years, the
United Nations and the World Health Organisation have recog-
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nised sickle cell disease as a global public health problem (WHO
2010) due to population mobility, with increased migration from
high-to low-frequency sickle haemoglobin areas. Combined with
the global increase in population size, reduction in child mortality
and improved adult survival, the worldwide burden of sickle cell
disease is predicted to increase during the next several decades (Al
Hajeri 2007; Martí-Carvajal 2009; Piel 2013).
Epidemiologically, it is estimated that somewhere between5%(ap-
proximately 367 million people) (WHO 2011) and 7% (approxi-
mately 500 million people) (Weatherall 2001) of the world’s pop-
ulation are carriers of the mutant haemoglobin gene. The preva-
lence of sickle cell disease in a given population is determined by
the prevalence of the sickle cell trait. If the prevalence of the trait
is around 25% in a given population, then the prevalence of the
disease at birth can be estimated to be approximately 2% (Cook
2003; WHO 2010).
Sickle cell disease is the most common inherited blood disorder
globally.Worldwide, the African region has the highest prevalence
with approximately 200,000 babies born with sickle cell disease
every year (Diallo 2002; Martí-Carvajal 2009). In 2010, approxi-
mately 75% of the globally estimated homozygous sickle cell dis-
ease newborns were from Sub-Saharan Africa (Piel 2013). In the
United States, the prevalence of sickle cell disease is approximately
100,000 and it predominantly affects Americans of African de-
scent (NIH 2015). In addition to this, 3.5 million African-Ameri-
cans have the sickle cell trait HbAS genotype (i.e. are heterozygote
carriers of sickle haemoglobin) (Yawn 2014). The United King-
dom reports a prevalence of approximately 12,500 people with
the disease (National Screening Committee 2006).
Shortened lifespans are attributable to serious co-morbidities asso-
ciated with the disease, including renal failure, pulmonary hyper-
tension, pulmonary embolus, stroke, acute chest syndrome and
sepsis (Tanabe 2012). For example, African-Americans with sickle
cell disease have a life expectancy of 48 for females and 42 for
males, compared with the life expectancy of African-Americans
without sickle cell disease of 77 and 71 (respectively) (Platt 1994;
Tanabe 2012). However, there is uncertainty in these estimates as
different countries report longer median survival rates. For exam-
ple, the median survival rate of the Jamaican sub-population is
58.5 years for females and 53 for males (Wierenga 2001).
Sickle cell disease is characterised by the presence of distorted
sickle-shaped red blood cells in the blood stream. These sickle-
shaped cells arise as a result of the “polymerisation (gelling of the
molecules) of the abnormal haemoglobin in the red blood cells
when they release their combined oxygen” (Al Hajeri 2007).Many
manifestations of the disease are attributed to either haemolysis
(premature red cell destruction) or vaso-occlusion (obstruction
of blood flow), which is the most common manifestation (Al
Hajeri 2007). Red cell dehydration contributes to vaso-occlusion:
dehydrated red cells adhere to vascular endothelium, which results
in blockage of blood flow (Lutz 2015). Other severe outcomes
of the manifestations of sickle cell disease can include acute chest
syndrome (chest crisis), priapism, acute cholecystitis, acute stroke
and aplastic crisis (NIH 2014).
Vaso-occlusion can lead to acute, painful crisis. This is also known
as a sickle cell crisis, vaso-occlusive crisis or vaso-occlusive episode.
Pain is most often reported in the joints, extremities, back or chest,
but it can occur anywhere and can last for several days or weeks.
The frequency and severity of the painful episodes vary widely
within and between individuals. The peak incidence is in late ado-
lescence and early adulthood (Ballas 2007). The bone and muscle
pain experienced during a sickle cell crisis is both acute (sudden
onset of severe intensity) and recurrent (reoccurring unpredictably
and intermittently over long periods of time whilst fluctuating in
frequency and quality) (Serjeant 1994; Thienhaus 2002).
This review will focus on the vaso-occlusive manifestation of the
disease, which causes the acute and painful crises (episodes). It will
exclude the other possible outcomes in sickle cell disease patients.
Description of the intervention
A vaso-occlusive crisis can require several interventions, depending
on the patient and situation. Treatment for vaso-occlusive crisis
is primarily symptomatic and aims to stabilise pain. As well as
pharmacological agents, non-pharmacological approaches, such as
relaxation, hypnosis, heat, ice and acupuncture, have been used to
rehydrate the patient and reduce the sickling process (Ballas 2005;
Ballas 2007; De Ceulaer 1982; Gaston 1986; Lane 2001; Okomo
2015).
In this review, we will assess pharmacological interventions used
to treat vaso-occlusive crises in adults living with sickle cell dis-
ease. These include (but are not limited to) analgesic opioids, non-
analgesic opioids, partial agonists, mixed agonists-antagonists, an-
tagonists and adjuvants (Ballas 2007).
In context, a vaso-occlusive crisis is the hallmark of sickle cell dis-
ease and is the most common cause of hospitalisation in patients
(up to 90%) (Ballas 2005; Dampier 2013). Therefore, treatment
for adults with vaso-occlusive crisis is usually on presentation to
an emergency healthcare facility, where the patient should (in in-
dustrialised countries) receive treatment if they report 30 minutes
or more of acute and debilitating pain (Lanzkron 2015). In addi-
tion, some sickle cell disease patients often self medicate at home
with pharmacological agents. In both settings, primary manage-
ment should be focused on rapid pain control, whereby fluids and
analgesics should be administered immediately (NICE 2015).
Vaso-occlusive crisis can be treated with various drugs (described
below). As with all pharmacotherapies, the risk of adverse effects
can be minimised by prescribing the lowest dose for the shortest
duration possible to control the symptoms (NICE 2015).
For all analgesia, the patient’s respiratory rate, pain and sedation are
assessed at 20-minute intervals until pain control is reached, then
monitored with analgesia re-administered every four hours (NICE
2015; Rees 2003). Patient-controlled administration (PCA) is also
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an option and commonly used in adolescents transitioning into
adult care (Telfer 2014).
A. Opioid analgesics are recommended as the primary choice
of pain relief in vaso-occlusive crisis management (NICE
2015). They include (but are not limited to): codeine, hy-
drocodone/paracetamol (acetaminophen), hydrocodone/ibupro-
fen, oxycodone (and with codeine), morphine, hydromorphone,
oxymorphone, methadone, diamorphine and fentanyl (Ballas
2007). Opioids are generally available in healthcare settings in
most Western countries and are often delivered as intravenous
morphine every four to six hours. In addition, oral opioids are also
prescribed as patient-administered analgesia after a vaso-occlusive
crisis episode (NICE 2015).
Most analgesic opioids have a half-life of two to four hours, with
the exception of methadone, propoxyphene and meperidine, for
which this can be one to several days (Trescot 2008). Although
the standard dosing is generally every four to six hours, some pa-
tients develop tolerance to opioids, thus requiring doses every two
hours (Okpala 2002). Combination with diclofenac or paraceta-
mol (which have different mechanisms of action) will help to keep
opioid use to a minimum (Okpala 2002).
The adverse effects of analgesic opioids include: (short-term)
respiratory depression, constipation, vomiting, nausea, pruritus
and hives (Ballas 2007), addiction and withdrawals (Rosenblum
2008).
B. Non-opioid analgesics are the other drugs of choice for
managing a vaso-occlusive crisis (NICE 2015). These include:
acetaminophen (paracetamol), non-selective COX inhibitors
(acetylsalicylic acid, ibuprofen, naproxen, ketorolac) and selective
COX-2 inhibitors (celecoxib) (Ballas 2007).
Themost commonly used drugs from this family are non-steroidal
anti-inflammatory drugs (NSAIDs), paracetamol, diclofenac and
ketorolac. They are commonly used for mild to moderate pain
either alone or in combination with opioid analgesia (Rees 2003).
NSAIDs are available in most countries. The adverse effects of
NSAIDs include gastrointestinal complications and they should
be administered with caution in patients with a history of renal
failure, bleeding tendencies, asthma or peptic ulcer (Rees 2003).
Paracetamol is also widely available in Western countries and is
administered orally at a dosage of 200 mg to 500 mg every four
to six hours until satisfactory pain relief has been achieved. The
adverse effects of paracetamol are influenced by the dosage and
duration of use and can include liver failure (Rees 2003).
C. Other pharmacotherapeutic drugs to be considered for anal-
ysis in this review include partial agonists (examples include
buprenorphine and buprenorphine/naloxone), mixed agonist-an-
tagonists (examples include pentazocine, nalbuphine and butor-
phanol) and hydroxyurea (Ballas 2007). Finally, we will also con-
sider any other pharmacotherapeutic drugs that we find, which
are used to treat vaso-occlusive crisis.
How the intervention might work
Analgesics work in a number of different ways to treat vaso-occlu-
sive crisis, thus the key factor is whether the drugs provide relief
of participant-reported pain. Therefore, we are interested in gath-
ering a comprehensive list of all pharmacotherapeutic treatments
that have been trialled in a clinical setting to treat an episode (new
or recurrent) in diagnosed sickle cell disease patients. We are also
interested in combination drug therapies.
Why it is important to do this review
Globally, sickle cell disease is one of the four most common auto-
somal recessive disorders, along with thalassaemia, Tay-Sachs dis-
ease and cystic fibrosis (Hussein 2015). In addition, in many in-
dustrialised countries there has been an improvement in the sur-
vival rate of children with sickle cell disease who now live on into
adulthood (approximately 98.4%), thus increasing the adult pop-
ulation living with this condition (Quinn 2010; Sasongko 2013).
We are unaware of any recent or up-to-date systematic reviews that
draw on comparisons of a full range of pharmacotherapies used
specifically to treat vaso-occlusive crisis in adults. Therefore, this
review will aim to address and analyse all available pharmacother-
apies, including drug combinations.
This systematic review will also address the issue of tolerance or
habituation to opioids where this is reported in sickle cell disease
patients (Tanabe 2012; Waldrop 1995). Regular analgesia should
be given for acute pain when presenting in the emergency setting.
Due to patients developing a tolerance and requiring more fre-
quent doses, it has been suggested that every effort should be made
to prevent such tolerance developing in new patients because there
is a limited choice of injectable opioids that can be used in acute
painful episodes (Okpala 2002). In recent qualitative surveys of
health professionals, there is a common view, despite a lack of ev-
idence, that compared to all emergency department patients pre-
senting with pain a higher frequency of sickle cell disease patients
are addicted to opioids and that they are usually seeking out drugs
for this dependency (Tanabe 2012;Waldrop 1995). Continuity of
care can be lacking for people with sickle cell disease, reiterating
the fact that up-to-date clinical guidance for health profession-
als in primary care and emergency care is critically needed (Yawn
2014). Therefore it is important to conduct this review to investi-
gate combination analgesics that have different mechanisms of ac-
tion, in order to keep opioid doses to a minimum (Okpala 2002).
A systematic review of the current evidence on the reported ben-
efits and harms is required to clarify the most effective pharma-
cotherapeutic options (and combinations) for effective pain relief
interventions in adult patients with acute painful sickle cell vaso-
occlusive crises.
O B J E C T I V E S
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To assess the analgesic efficacy, and adverse events, of pharmaco-
logical interventions used to treat acute painful sickle cell vaso-
occlusive crises in adults, aged 18 and over, in any setting.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) with dou-
ble-blind assessment of participant outcomes following immediate
treatment for acute painful sickle cell vaso-occlusive episodes. We
will also consider cross-over studies. We require full journal publi-
cation, with the exception of online clinical trial results, summaries
of otherwise unpublished clinical trials and extended abstracts of
otherwise unpublished clinical trials if sufficient data can be anal-
ysed. We will exclude studies that are non-randomised, studies of
experimental pain, case reports and clinical observations.
Types of participants
Studies will include adult participants, aged 18 years and above,
who are diagnosed with sickle cell disease and who have an acute
painful sickle cell vaso-occlusive crisis (new or recurring).
We will consider including studies that contain some participants
below 18 years (such as adolescent participants mixed with adult
participants over 18 years). In this case we will extract the data on
participants aged 18 years and above. We will contact the authors
of trials for the separate adult data if necessary.
Types of interventions
Any pharmacological intervention at any dose, by any route, ad-
ministered for the relief of acute pain associated with a sickle cell
vaso-occlusive episode or event (new or recurring) and compared
to placebo or any active comparator.
We will include studies treating the crisis in any health setting, as
well as combination drug regimes. Intravenous fluid replacement
therapy is a primary step in the NICE guidelines for managing a
sickle cell crisis (NICE 2015) and is therefore considered standard
practice and not an active comparator for the purpose of this re-
view. We will not include studies using agents to treat pain result-
ing from other causes. We will not include studies using agents
to attempt to treat the cause of sickle cell disease, chronic pain or
non-painful symptoms of the disease.
Types of outcome measures
Studies must report pain assessment as either a primary or sec-
ondary outcome to be eligible for this review.
We anticipate that studies will use a variety of outcome measures,
with the majority of studies using standard subjective scales (nu-
merical rating scale (NRS) or visual analogue scale (VAS)) for pain
intensity or pain relief, or both (Dworkin 2008).
We will use the following dichotomous measures of pain: at least
50% pain relief over baseline (substantial), at least 30% pain re-
lief over baseline (moderate), very much improved on the Patient
Global Impression of Change (PGIC) (substantial), and much or
very much improved on the PGIC (moderate). These outcomes
are different from those used inmost earlier reviews (Wiffen 2005),
and we recognise that continuous responses to chronic pain gen-
erally do not follow a normal (Gaussian) distribution. People with
chronic pain desire high levels of pain relief, ideally more than
50% and ideally leading to nomore thanmild pain (Moore 2013a;
O’Brien 2010). For the purpose of this review, we consider it ap-
propriate to adapt these measurements of chronic pain to acute
painful episodes.
We will include a ’Summary of findings’ table as set out in the
author guide (PaPaS 2012). The ’Summary of findings’ table will
include outcomes of at least 30% and at least 50% pain intensity
reduction, PGIC, withdrawals due to adverse events, serious ad-
verse events and death.Wewill use theGRADE approach to assess
the quality of the evidence related to each of the key outcomes
listed in here (Chapter 12, Higgins 2011), as appropriate.
Primary outcomes
• Participant-reported pain relief of 50% or greater at 6, 12,
24, 48 hours and at the end of treatment.
• Participant-reported pain relief of 30% or greater at 6, 12,
24, 48 hours and at the end of treatment.
• Patient global impression of change (PGIC) very much
improved.
• Patient global impression of change (PGIC) much or very
much improved.
Secondary outcomes
• Opioid consumption.
• Time to pain resolution.
• Length of hospitalisation.
• Participants experiencing any adverse or serious adverse
event. Serious adverse events typically include any untoward
medical occurrence or effect that at any dose results in death, is
life-threatening, requires hospitalisation or prolongation of
existing hospitalisation, results in persistent or significant
disability or incapacity, is a congenital anomaly or birth defect, is
an ’important medical event’ that may jeopardise the patient, or
may require an intervention to prevent one of the above
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characteristics or consequences. Acute chest syndrome is well
documented as a reported adverse event of vaso-occlusive crisis
and we will assess the issues around tolerability of the drugs.
• Any pain-related outcome indicating some improvement,
such as sleep quality or activities of daily living.
• Withdrawals due to lack of efficacy, adverse events and for
any cause.
• Reports of tolerance or habituation to opioids.
These secondary outcomes are not eligibility criteria for this review,
but are outcomes of interest withinwhichever studies are included.
Search methods for identification of studies
The Information Specialist will carry out the searches.
Electronic searches
We will search the following databases without language restric-
tions:
• Cochrane Central Register of Controlled Trials
(CENTRAL) (via The Cochrane Library);
• MEDLINE (via Ovid);
• EMBASE (via Ovid);
• LILACS.
We will use medical subject headings (MeSH) or equivalent and
text-word terms. We will tailor the searches to the individual
databases.
The search strategy for MEDLINE is in Appendix 1.
Searching other resources
Wewill search themetaRegister of controlled trials (mRCT) (http:/
/www.isrctn.com/), ClinicalTrials.gov (www.clinicaltrials.gov)
and the World Health Organisation (WHO) International
Clinical Trials Registry Platform (ICTRP) (http://apps.who.int/
trialsearch/) for ongoing trials. In addition,we will check the ref-
erence lists of reviews and retrieved articles for additional studies
and perform citation searches on key articles.
Data collection and analysis
Selection of studies
Two review authors (TC and SB) will independently determine
eligibility by reading the title and abstract of each study identi-
fied by the search. The independent review authors will eliminate
studies that clearly do not satisfy the inclusion criteria and obtain
full copies of the remaining studies.
Two review authors (TC and SB) will read these reports indepen-
dently to select relevant studies. In the event of disagreement, a
third author will adjudicate (PW). We will not anonymise the
studies in any way before assessment. We will include a Pre-
ferred Reporting Items for Systematic Reviews andMeta-Analyses
(PRISMA) flow chart in the full review, which will show the status
of identified studies (Moher 2009), as recommended in Part 2,
Section 11.2.1 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).We will include studies in the review
irrespective of whether measured outcome data are reported in a
’usable’ way.
Data extraction and management
Two review authors (TC and IH) will independently extract data
using a standard form and check for agreement before entry into
Review Manager (RevMan 2014).
We will include information about the pain condition, number
of participants treated, drug and dosing regimen, study design
(placeboor active control), study duration and follow-up, analgesic
outcome measures and results, withdrawals and adverse events
(participants experiencing any adverse event or serious adverse
event).
We will collate multiple reports of the same study, so that each
study rather than each report is the unit of interest in the review.
We will collect characteristics of the included studies in sufficient
detail to populate a table of ’Characteristics of included studies’ in
the full review.
Assessment of risk of bias in included studies
Two authors (TC and SB) will independently assess risk of bias for
each study, using the criteria outlined in theCochraneHandbook for
Systematic Reviews of Interventions (Higgins 2011), adapted from
those used by the Cochrane Pregnancy and Childbirth Group,
with any disagreements resolved by discussion. We will complete
a ’Risk of bias’ table for each included study using the ’Risk of
bias’ tool in Review Manager (RevMan) (RevMan 2014).
We will assess the following for each study.
• Random sequence generation (checking for possible
selection bias). We will assess the method used to generate the
allocation sequence as: low risk of bias (any truly random
process, e.g. random number table; computer random number
generator); unclear risk of bias (method used to generate
sequence not clearly stated). We will exclude studies using a non-
random process (e.g. odd or even date of birth; hospital or clinic
record number).
• Allocation concealment (checking for possible selection
bias). The method used to conceal allocation to interventions
prior to assignment determines whether intervention allocation
could have been foreseen in advance of, or during, recruitment
or changed after assignment. We will assess the methods as: low
risk of bias (e.g. telephone or central randomisation;
consecutively numbered, sealed, opaque envelopes); unclear risk
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of bias (method not clearly stated). We will exclude studies that
do not conceal allocation (e.g. open list).
• Blinding of outcome assessment (checking for possible
detection bias). We will assess the methods used to blind study
participants and outcome assessors from knowledge of which
intervention a participant received. We will assess the methods
as: low risk of bias (study states that it was blinded and describes
the method used to achieve blinding, e.g. identical tablets;
matched in appearance and smell); unclear risk of bias (study
states that it was blinded but does not provide an adequate
description of how it was achieved). We will exclude studies that
were not double-blind.
• Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data). We will assess the methods used to deal with
incomplete data as: low risk (less than 10% of participants did
not complete the study or used ’baseline observation carried
forward’ analysis, or both); unclear risk of bias (used ’last
observation carried forward’ analysis); high risk of bias (used
’completer’ analysis).
• Size of study (checking for possible biases confounded by
small size). We will assess studies as being at low risk of bias (200
participants or more per treatment arm); unclear risk of bias (50
to 199 participants per treatment arm); high risk of bias (fewer
than 50 participants per treatment arm).
Measures of treatment effect
We will use dichotomous data to calculate risk ratios (RR) with
95% confidence intervals (CI) using a fixed-effect model unless
significant statistical heterogeneity is found (see below).
We will calculate NNTs as the reciprocal of the absolute risk re-
duction (ARR; McQuay 1998). For unwanted effects, the NNT
becomes the number needed to treat to harm (NNH) and is calcu-
lated in the same manner. Where the unwanted effect is less com-
mon with treatment than control, we will use the term number
needed to treat to prevent (NNTp).
We will not use continuous data in analyses because it is inappro-
priate where there is underlying skewed distribution, as is usually
the case with analgesic response.
Unit of analysis issues
We expect that for all included studies, the unit of analysis will
be at the participant level, with each participant providing one
pain episode per trial. It is possible, though unlikely, that a trial
may include multiple pain events per participant, introducing a
clustering effect. In this scenario we will use the number of trial
clusters and an estimate of the intra class correlation coefficient to
inflate the standard errors associated with each clustered trial.
Assessment of heterogeneity
When possible, we will deal with clinical heterogeneity (variation
in participants, interventions or outcomes) by combining studies
that examine similar conditions. We will assess statistical hetero-
geneity visually (L’Abbé 1987), and with the use of the I² statistic.
When the I² value is greater than 50%, we will consider the pos-
sible reasons for this.
Assessment of reporting biases
The aim of this review is to use dichotomous outcomes of known
utility and of value to patients (Hoffman 2010; Moore 2010b;
Moore 2010c; Moore 2010d; Moore 2013a). The review will not
depend on what the authors of the original studies chose to report
or not, though clearly difficulties will arise in studies failing to re-
port any dichotomous results. We will extract and use continuous
data, which will probably poorly reflect efficacy and utility and
may be useful for illustrative purposes only.
We will assess publication bias using a method designed to detect
the amount of unpublished datawith a null effect required tomake
any result clinically irrelevant (usually taken to mean a NNT of
10 or higher; Moore 2008).
Data synthesis
We plan to use a fixed-effect model for meta-analysis. We will
use a random-effects model for meta-analysis if there is significant
clinical heterogeneity and it is considered appropriate to combine
studies. We will use the Cochrane software program Review Man-
ager (RevMan 2014).
Two review authors (TC, SB)will independently rate the quality of
the evidence for each outcome.Wewill use theGRADE (Grades of
Recommendation, Assessment,Development andEvaluation) sys-
tem to rank the quality of the evidence using the GRADEprofiler
Guideline Development Tool software (GRADEpro GDT 2015),
and the guidelines provided inChapter 12.2 of theCochraneHand-
book for Systematic Reviews of Interventions (Higgins 2011).
TheGRADE approach uses five considerations (study limitations,
consistency of effect, imprecision, indirectness and publication
bias) to assess the quality of the body of evidence for each outcome.
The GRADE system uses the following criteria for assigning the
grade of evidence:
• High: further research is very unlikely to change our
confidence in the estimate of effect;
• Moderate: further research is likely to have an important
impact on our confidence in the estimate of effect and may
change the estimate;
• Low: further research is very likely to have an important
impact on our confidence in the estimate of effect and is likely to
change the estimate;
• Very low: any estimate of effect is very uncertain.
We will decrease the grade due to:
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• serious (-1) or very serious (-2) limitation to study quality;
• important inconsistency (-1);
• some (-1) or major (-2) uncertainty about directness;
• imprecise or sparse data (-1);
• high probability of reporting bias (-1).
Subgroup analysis and investigation of heterogeneity
We do not plan any subgroup analyses since experience from pre-
vious reviews suggests a limited chance of sufficient data. How-
ever, we will consider subgroup classification between genotypes
should the data be available.
Sensitivity analysis
We plan no sensitivity analysis because the evidence base is known
to be too small to allow reliable analysis. We will not pool results
from sickle cell pain pain of different origins in the primary anal-
yses. We will examine details of dose escalation schedules in the
unlikely situation that this could provide some basis for a sensi-
tivity analysis.
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Appendix 1. MEDLINE search strategy (via Ovid)
1 exp Anemia, Sickle Cell/
2 sickle cell.tw.
3 “SCD”.tw.
4 “sickling disorder”.tw.
5 “HBS”.tw.
6 (haemoglobin adj1 disease).tw.
7 (haemoglobin adj1 disease).tw.
8 or/1-7
9 exp Pain/
10 pain*.tw.
11 or/9-10
12 (acetaminophen or “acetylsalicylic acid” or “alendronic acid” or alfentanil or amitriptyline or aspirin or baclofen or benzocaine or
bupivacaine or buprenorphine or butorphanol or carbamazepine or chloroprocaine or “choline magnesium trisalicylate” or clonazepam
or clonidine or codeine or dexamethasone or dexmetetomidine or dextroamphetamine or dextropropoxyphene or diamorphine or
diazepam or diclofenac or dihydrocodeine or domperidone or fentanyl or fluoxetine or gabapentin or hydrocodone or hydromorphone
or “hyoscine hydrobromide” or ibuprofen or ketamine or ketoprofen or ketorolac or “levo bupivacaine” or lidocaine or loperamide
or lorazepam or mefenamic acid or meperidine or methadone or methylphenidate or midazolam or morphine or naproxen or nitrous
oxide or nortriptyline or oxycodone or pamidronate or paracetamol or paroxetine or pentazocine or pethidine or phenobarbital or
“phenytoin” or piroxicam or pregabalin or propoxyphene or “risedronate sodium” or “sodium clodronate” or tetracaine or tramadol or
“valproic acid”).tw.
13 exp Analgesics/
14 Anesthesia, Local/
15 exp Anti-Inflammatory Agents, Non-Steroidal/
16 or/12-15
17 8 and 11 and 16
18 randomized controlled trial.pt.
19 controlled clinical trial.pt.
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20 randomized.ab.
21 placebo.ab.
22 drug therapy.fs.
23 randomly.ab.
24 trial.ab.
25 groups.ab.
26 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25
27 exp animals/ not humans.sh.
28 26 not 27
29 17 and 28
Appendix 2. EMBASE search strategy (via Ovid)
1 exp Anemia, Sickle Cell/
2 sickle cell.tw.
3 “SCD”.tw.
4 “sickling disorder”.tw.
5 “HBS”.tw.
6 (haemoglobin adj1 disease).tw.
7 (haemoglobin adj1 disease).tw.
8 or/1-7
9 exp Pain/
10 pain*.tw.
11 or/9-10
12 (acetaminophen or “acetylsalicylic acid” or “alendronic acid” or alfentanil or amitriptyline or aspirin or baclofen or benzocaine or
bupivacaine or buprenorphine or butorphanol or carbamazepine or chloroprocaine or “choline magnesium trisalicylate” or clonazepam
or clonidine or codeine or dexamethasone or dexmetetomidine or dextroamphetamine or dextropropoxyphene or diamorphine or
diazepam or diclofenac or dihydrocodeine or domperidone or fentanyl or fluoxetine or gabapentin or hydrocodone or hydromorphone
or “hyoscine hydrobromide” or ibuprofen or ketamine or ketoprofen or ketorolac or “levo bupivacaine” or lidocaine or loperamide
or lorazepam or mefenamic acid or meperidine or methadone or methylphenidate or midazolam or morphine or naproxen or nitrous
oxide or nortriptyline or oxycodone or pamidronate or paracetamol or paroxetine or pentazocine or pethidine or phenobarbital or
“phenytoin” or piroxicam or pregabalin or propoxyphene or “risedronate sodium” or “sodium clodronate” or tetracaine or tramadol or
“valproic acid”).tw.
13 exp Analgesics/
14 Anesthesia, Local/
15 exp Anti-Inflammatory Agents, Non-Steroidal/
16 or/12-15
17 8 and 11 and 16
18 Randomized controlled trial/
19 Controlled clinical study/
20 18 or 19
21 Random$.ti,ab.
22 randomization/
23 intermethod comparison/
24 placebo.ti,ab.
25 (compare or compared or comparison).ti.
26 ((evaluated or evaluate or evaluating or assessed or assess) and (compare or compared or comparing or comparison)).ab.
27 (open adj label).ti,ab.
28 ((double or single or doubly or singly) adj (blind or blinded or blindly)).ti,ab.
29 double blind procedure/
30 parallel group$1.ti,ab.
31 (crossover or cross over).ti,ab.
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32 ((assign$ or match or matched or allocation) adj5 (alternate or group$1 or intervention$1 or patient$1 or subject$1 or partici-
pant$1)).ti,ab.
33 (assigned or allocated).ti,ab.
34 (controlled adj7 (study or design or trial)).ti,ab.
35 (volunteer or volunteers).ti,ab.
36 human experiment/
37 trial.ti.
38 or/20-37
39 17 and 38
Appendix 3. CENTRAL search strategy (via CRSO)
#1 MeSH DESCRIPTOR Anemia, Sickle Cell EXPLODE ALL TREES
#2 (sickle cell):TI,AB,KY
#3 “SCD”:TI,AB,KY
#4 (“sickling disorder”):TI,AB,KY
#5 “HBS”:TI,AB,KY
#6 ((haemoglobin near1 disease)):TI,AB,KY
#7 ((haemoglobin near1 disease)):TI,AB,KY
#8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 30
#9 MeSH DESCRIPTOR Pain EXPLODE ALL TREES
#10 pain*:TI,AB,KY
#11 #9 OR #10
#12 ((acetaminophen or “acetylsalicylic acid” or “alendronic acid” or alfentanil or amitriptyline or aspirin or baclofen or benzocaine or
bupivacaine or buprenorphine or butorphanol or carbamazepine or chloroprocaine or “choline magnesium trisalicylate” or clonazepam
or clonidine or codeine or dexamethasone or dexmetetomidine or dextroamphetamine or dextropropoxyphene or diamorphine or
diazepam or diclofenac or dihydrocodeine or domperidone or fentanyl or fluoxetine or gabapentin or hydrocodone or hydromorphone
or “hyoscine hydrobromide” or ibuprofen or ketamine or ketoprofen or ketorolac or “levo bupivacaine” or lidocaine or loperamide
or lorazepam or mefenamic acid or meperidine or methadone or methylphenidate or midazolam or morphine or naproxen or nitrous
oxide or nortriptyline or oxycodone or pamidronate or paracetamol or paroxetine or pentazocine or pethidine or phenobarbital or
“phenytoin” or piroxicam or pregabalin or propoxyphene or “risedronate sodium” or “sodium clodronate” or tetracaine or tramadol or
“valproic acid”)):TI,AB,KY
#13 MeSH DESCRIPTOR Analgesics EXPLODE ALL TREES
#14 MeSH DESCRIPTOR Anesthesia, Local
#15 MeSH DESCRIPTOR Anti-Inflammatory Agents, Non-Steroidal EXPLODE ALL TREES
#16 #12 OR #13 OR #14 OR #15
#17 #8 AND #11 AND #16
Appendix 4. LILACS search strategy
(sickle cell) or SCD or (sickling disorder) or HBS or (haemoglobin disease) or (haemoglobin disease) [Words] and pain$ [Words]
and (acetaminophen or (acetylsalicylic acid) or (alendronic acid) or alfentanil or amitriptyline or aspirin or baclofen or benzocaine or
bupivacaine or buprenorphine or butorphanol or carbamazepine or chloroprocaine or (choline magnesium trisalicylate) or clonazepam
or clonidine or codeine or dexamethasone or dexmetetomidine or dextroamphetamine or dextropropoxyphene or diamorphine or
diazepam or diclofenac or dihydrocodeine or domperidone or fentanyl or fluoxetine or gabapentin or hydrocodone or hydromorphone
or (hyoscine hydrobromide) or ibuprofen or ketamine or ketoprofen or ketorolac or (levo bupivacaine) or lidocaine or loperamide or
lorazepam or mefenamic acid or meperidine or methadone or methylphenidate or midazolam or morphine or naproxen or nitrous
oxide or nortriptyline or oxycodone or pamidronate or paracetamol or paroxetine or pentazocine or pethidine or phenobarbital or
(phenytoin) or piroxicam or pregabalin or propoxyphene or (risedronate sodium) or (sodium clodronate) or tetracaine or tramadol or
(valproic acid)) [Words]
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